<DOC>
	<DOC>NCT00573794</DOC>
	<brief_summary>To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis.</brief_summary>
	<brief_title>Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must have successfully enrolled and completed either the M06826 study or the M06827 study Subject is judged to be in generally good health as determined by the principal investigator Subject has not responded to weekly adalimumab therapy in M06826 or M06827 Subject considered by the investigator, for any reason, to be an unsuitable candidate Female subject who is pregnant or breastfeeding or considering becoming pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ulcerative Colitis</keyword>
</DOC>